RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome

AIMS: To establish the safety, tolerability and most promising regimen of darexaban (YM150), a novel, oral, direct factor Xa inhibitor, for prevention of ischaemic events in acute coronary syndrome (ACS). METHODS: In a 26-week, multi-centre, double-blind, randomized, parallel-group study, 1279 patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Steg, Ph. Gabriel, Mehta, Shamir R., Jukema, J. Wouter, Lip, Gregory Y.H., Gibson, C. Michael, Kovar, Frantisek, Kala, Petr, Garcia-Hernandez, Alberto, Renfurm, Ronny W., Granger, Christopher B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Fasttrack
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295208/
https://www.ncbi.nlm.nih.gov/pubmed/21878434
http://dx.doi.org/10.1093/eurheartj/ehr334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295208/
https://www.ncbi.nlm.nih.gov/pubmed/21878434
http://dx.doi.org/10.1093/eurheartj/ehr334

Ejemplares similares